Subscribe

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)

HKD0.93 +0.03 (+3.33%)
CN HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address Office Tower, Convention Plaza
Beijing, CN
CEO Wei Cheng Guo
Website sihuanpharm.com
IPO 2010-10-28
ISIN BMG8162K1137

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 0460.HK (HKD) Other OTC · SHPHF (USD)
Description

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China and the United States. It operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions. It also provides drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. In addition, the company involved in the provision of research and development, and industrialization of innovative medicine; construction for medical project; provision of general hospital services and hospital management services; and property investment business. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD0.93 +0.03 (+3.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
30M
Beta
0.88
Float Shares
3.71B
Free Float %
41.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.05% -7.69% -24.41% -38.06% -28.89% -21.95% -2.04% +29.73% -74.74% -38.46% -66.78%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.93
DCF (Unlevered) 0.01 -99.4%
DCF (Levered) 0.15 -84.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.73
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +37.7% ★ Q4'25: +82.9% (vs Q4'23)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +184.2% ★ Q4'25: +1,800.0% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -20.5% Q4'25: +2.9% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +18.2% ★ Q4'25: +18.4% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +7.7% ★ Q4'25: +17.5% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -1.5% ★ Q4'25: -2.5% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    1.42× ★ Q4'25: 0.67× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.97) × ERP
WACC = 89% × Ke + 11% × Kd (22.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.00 Current price: 0.93
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
3.17B
est: 4.25B (-25.4%)
3.19B
est: 3.20B (-0.3%)
2.75B
est: 3.30B (-16.7%)
2.92B
est: 3.07B (-4.8%)
2.88B
est: 3.61B (-20.3%)
2.46B
est: 2.59B (-4.9%)
3.04B
est: 4.50B (-32.4%)
2.18B
est: 3.22B (-32.3%)
1.86B
est: 2.17B (-14.4%)
1.90B
est: 2.15B (-11.5%)
2.62B
est: 2.55B (+2.5%)
3.70B
3.70B – 3.70B
+44.7% YoY
4.56B
4.56B – 4.56B
+23.2% YoY
5.25B
5.25B – 5.25B
+15.2% YoY
EBITDA
2.29B
est: -34.43M (+6,763.1%)
2.18B
est: -25.89M (+8,523.7%)
1.68B
est: -26.71M (+6,387.3%)
1.92B
est: -24.84M (+7,818.2%)
-2.06B
est: -29.26M (-6,952.1%)
714.06M
est: -20.99M (+3,501.3%)
931.69M
est: -36.45M (+2,656.4%)
-1.54B
est: -26.12M (-5,803.3%)
334.31M
est: -17.62M (+1,997.3%)
-208.66M
est: -36.46M (-472.3%)
642.61M
est: -43.33M (+1,583.0%)
-62.71M
-62.71M – -62.71M
-44.7% YoY
-77.29M
-77.29M – -77.29M
-23.2% YoY
-89.06M
-89.06M – -89.06M
-15.2% YoY
EBIT
2.07B
est: -512.71M (+504.7%)
1.94B
est: -385.65M (+601.9%)
1.47B
est: -397.82M (+468.3%)
1.72B
est: -369.95M (+565.9%)
-2.42B
est: -435.79M (-454.9%)
485.82M
est: -312.66M (+255.4%)
676.20M
est: -542.77M (+224.6%)
-1.91B
est: -388.97M (-391.5%)
108.08M
est: -262.42M (+141.2%)
-389.41M
est: -265.83M (-46.5%)
476.72M
est: -315.92M (+250.9%)
-457.23M
-457.23M – -457.23M
-44.7% YoY
-563.52M
-563.52M – -563.52M
-23.2% YoY
-649.32M
-649.32M – -649.32M
-15.2% YoY
Net Income
2.06B
est: 1.33B (+54.8%)
1.71B
est: 1.08B (+58.8%)
1.45B
est: 1.13B (+28.1%)
1.62B
est: 1.14B (+41.8%)
-2.75B
est: -905.62M (-204.0%)
473.38M
est: 468.78M (+1.0%)
416.51M
est: 795.61M (-47.6%)
-1.91B
est: 193.42M (-1,090.0%)
-54.02M
est: -341.56M (+84.2%)
-216.66M
est: -145.98M (-48.4%)
179.70M
est: 273.69M (-34.3%)
662.63M
662.63M – 662.63M
+142.1% YoY
1.07B
1.07B – 1.07B
+61.9% YoY
1.33B
1.33B – 1.33B
+23.5% YoY
SGA
610.96M
est: 1.95B (-68.7%)
686.23M
est: 1.47B (-53.3%)
552.74M
est: 1.51B (-63.5%)
667.23M
est: 1.41B (-52.6%)
716.95M
est: 1.66B (-56.8%)
858.58M
est: 1.19B (-27.9%)
1.13B
est: 2.07B (-45.4%)
1.02B
est: 1.48B (-30.9%)
911.22M
est: 998.98M (-8.8%)
1.18B
est: 1.02B (+15.1%)
1.12B
est: 1.21B (-7.9%)
1.76B
1.76B – 1.76B
+44.7% YoY
2.16B
2.16B – 2.16B
+23.2% YoY
2.49B
2.49B – 2.49B
+15.2% YoY
EPS
0.20
est: 0.14 (+39.1%)
0.17
est: 0.12 (+46.5%)
0.15
est: 0.12 (+22.9%)
0.17
est: 0.12 (+37.9%)
-0.29
est: -0.10 (-196.7%)
0.05
est: 0.05 (+6.1%)
0.04
est: 0.09 (-48.5%)
-0.21
est: 0.02 (-1,106.0%)
-0.01
est: -0.04 (+84.3%)
-0.02
est: -0.02 (-46.3%)
0.02
est: 0.03 (-34.3%)
0.07
0.07 – 0.07
+142.1% YoY
0.12
0.12 – 0.12
+61.9% YoY
0.15
0.15 – 0.15
+23.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B 3/5 3/5 3/5 4/5 3/5 1/5 3/5
2026-05-28 B 3/5 3/5 3/5 4/5 3/5 1/5 3/5
2026-05-27 B 3/5 3/5 3/5 4/5 3/5 1/5 3/5
2026-05-26 B 3/5 3/5 3/5 4/5 3/5 1/5 3/5
2026-05-22 B 3/5 3/5 3/5 4/5 3/5 1/5 3/5
2026-05-21 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-20 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-19 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-18 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-15 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-14 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-13 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-12 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-11 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-08 B- 2/5 3/5 2/5 3/5 2/5 1/5 3/5
2026-05-07 B- 2/5 3/5 2/5 3/5 2/5 1/5 3/5
2026-05-06 B- 2/5 3/5 2/5 3/5 2/5 1/5 3/5
2026-05-05 B- 2/5 3/5 2/5 3/5 2/5 1/5 3/5
2026-05-04 B- 2/5 3/5 2/5 3/5 2/5 1/5 3/5
2026-04-30 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-29 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-28 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-27 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-24 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-23 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-22 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-21 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-20 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-17 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-16 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
731.22M
OE per share TTM
0.08
Owner's Yield
8.43%
Maintenance CapEx ratio
1,110.13%
Maint CapEx / Avg PPE
133.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 58 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI China Small-Cap ETF ECNS 0.31% 200.2K 0.59%
2 State Street SPDR S&P Emerging Markets Small Cap ETF EWX 0.04% 306.8K 0.65%
3 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.04% 31.0K 0.74%
4 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.03% 202.0K 0.55%
5 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.03% 108.1K 0.72%
6 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.03% 99.4K 0.74%
7 Avantis Responsible Emerging Markets Equity ETF AVSE 0.02% 45.5K 0.33%
8 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.01% 16.4K 0.42%
9 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.01% 1.75M 0.06%
10 State Street SPDR S&P China ETF GXC 0.01% 46.7K 0.59%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
167.7K
Shares Outstanding
9.04B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Fengsheng Che Co-Founder & Executive Chairman 8M —
Xianhui Meng Deputy General Manager 5M male
Weicheng Guo Deputy Chairman & Chief Executive Officer 3M —
Guili Miao Deputy Chief Executive Officer, Chief Investment Officer, Chief Financial Officer & Executive Director 3M female
Yanling Chen Joint Company Secretary & Executive Director 2M female
Jionglong Zhang Executive Director 757.4K —
Kin Wai Li Joint Company Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic